Clinical Trials Logo

Overweight clinical trials

View clinical trials related to Overweight.

Filter by:

NCT ID: NCT04800835 Completed - Clinical trials for Overweight and Obesity

A Study to Compare the 12-month Spatz3 Adjustable Balloon With a 6-month Non Adjustable Balloon

Start date: February 15, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare a 12-month adjustable balloon over a 6-month non-adjustable balloon with 6-month dietician follow-up. The endpoint is %TBL at 12 months.

NCT ID: NCT04799132 Completed - Obesity Clinical Trials

Association Between Body Mass Index and HFNC Therapy Success

Start date: March 11, 2020
Phase:
Study type: Observational

Patients over 18 years of age who are admitted to the Intermediate Care Unit of the Clinica del Country and the Clinica la Colina, with symptoms suggestive of severe pneumonia secondary to COVID-19 infection and acute hypoxemic respiratory failure. The primary outcome will be to determine the relationship between body mass index and high-flow cannula therapy success defined as: No need for mechanical ventilation.

NCT ID: NCT04794244 Completed - Clinical trials for Overweight Adolescents

Healthy Living in Overweight and Obese Adolescents ASGE-FABES Program in Development of Formats

Start date: September 20, 2017
Phase: N/A
Study type: Interventional

The aim of this project is to develop multiple behavioral strategies for the prevention of obesity in adolescents. ASGE-FABES [Adolescent Health Promotion Physical Activity, Physical activity of overweight and obese youth of Nutrition, Stress Management] Program,to evaluate its effects on nutrition and mental health. Program overweight and obeseadolescents to lose weight in a healthy way, healthy lifestyle behaviors make healthy choices, nutritional and physical activity knowledgecognitive and It aims to gain behavioral skills. In the study, "pretest-posttest in randomized groupswith control group, with repeated measures & quot; experimental design type is used. The sample of the research,250 (125-experiment, 125-control) constituted an overweight and obese adolescent.

NCT ID: NCT04786925 Completed - Clinical trials for Overweight or Obesity

Precision Nutrition Strategies for Improving the Quality of Life of Pre-senior and Senior Populations

Start date: October 16, 2018
Phase: N/A
Study type: Interventional

The number and proportion of people aged 60 years old and over is increasing worldwide. Ageing is characterized by a progressive loss of physiological integrity, leading to impaired function and increased vulnerability to death. This deterioration is the primary risk factor for major chronic diseases including diabetes, cardiovascular disease, and neurodegenerative disorders. The incidence of chronic conditions frequently rises sharply with age, after long exposure to unhealthful lifestyles involving the consumption of unhealthy diets and physical inactivity. Consequently, integrated dietary strategies and actions are required to promote healthy ageing and target major causes of morbidity and mortality in senior populations. The promising field of precision nutrition is rising as a therapeutic approach that aims to design tailored dietary interventions to prevent and manage chronic diseases. Indeed, precision nutrition approaches contemplate the interindividual heterogeneity caused by genetic/epigenetic dissimilarities, individual facets such as age and gender, the lifestyle and environmental exposome diversity, microbiome variations, and singular behavioral/psychological features. On the other hand, the inclusion of potentially bioactive compounds and functional foods as promoters of healthy aging within personalised dietary patterns could be an effective strategy to delay the aging process and age-related chronic diseases. One of the main limitations of a dietary prescription is the lack of compliance, due to the complexity of the prescription itself and/or the lack of commitment of the individual. The inclusion of digital tools to empower and motivate individuals and to support them in the management of the dietary strategy could overcome this limitation. With this background, the general objective of this investigation is to design precision nutritional strategies based on the inclusion of functional foods and digital tools for preventing age-related chronic diseases in pre-senior and senior populations. Additionally, this study proposes alternative tools for cognitive assessments increasing the accessibility to cognitive assessment tools for this population as well as an innovative digital tool for cognitive stimulation which is personalized, monitored, and evidence-based.

NCT ID: NCT04782024 Completed - Clinical trials for Resting Metabolic Rate

A Study to Investigate the Effect of 7-Keto on Resting Metabolic Rate in Overweight Adults

15KMHI
Start date: September 30, 2015
Phase: Phase 2
Study type: Interventional

This study will investigate the effect of two different doses of 7-Keto compared to placebo on resting metabolic rate. One third of subjects will be given the lower 7-Keto dose, one third will be given the higher 7-Keto dose and one third will be given the placebo.

NCT ID: NCT04781998 Completed - Clinical trials for Overweight and Obesity

Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?

Start date: July 1, 2021
Phase: Phase 4
Study type: Interventional

An open-label, multi-centre, 26-weeks clinical feasibility study. The objective is to explore whether Saxenda could be a feasible choice in the treatment of overweight, obesity and weight-related medical problems, in patients diagnosed with a severe mental illness and hospitalized at a forensic department in Denmark. We wish to determine the viability of the daily Saxenda®-injection treatment in this specific patient group.

NCT ID: NCT04773977 Completed - Overweight/Obesity Clinical Trials

Clinical Study of IBI362 in Healthy Chinese Male Subjects

Start date: March 3, 2021
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362 lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.

NCT ID: NCT04773483 Completed - Clinical trials for Overweight and Obesity

Quorn in Community Health Experiment

QUICHE
Start date: November 9, 2020
Phase: N/A
Study type: Interventional

In overweight individuals (BMI > 27.5 kg/m2), does daily consumption of mycoprotein containing Quorn Food products lower blood cholesterol compared with daily meat/fish consumption?

NCT ID: NCT04761406 Completed - Clinical trials for Overweight and Obesity

Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management

PHAEOSOL-ONE
Start date: April 26, 2021
Phase: N/A
Study type: Interventional

PhaoeSOL (Microphyt, Baillargues, France) is a microalgae-based nutritional ingredient developed with a patented production process that has New Dietary Ingredient (NDI) status from the FDA (#1120). It is an extract of the microalgae Phaeodactylum tricornutum standardized to 2.0% Fucoxanthin (FX) content by adding a food grade medium-chain triglyceride (MCT)-oil and a tocopherol-rich (Vitamin E) extract (0.5 % w:w). PhaeoSOL is intended for use as a source of the naturally occurring carotenoid, fucoxanthin, in food supplement products for the general population at levels not to exceed 437 mg/person/day for a maximal duration of 30 days of PhaeoSOL (equivalent to 10 mg fucoxanthin/person/day). Prior studies suggest that marine algae and Fucoxanthinol may have anti-obesity, lipid lowering, and glucose management enhancing properties. The purpose of this proof of concept pilot study is to examine whether dietary supplementation of PhaoeSOL enhances the benefits of women participating in an exercise and weight management program.

NCT ID: NCT04760951 Completed - Atherosclerosis Clinical Trials

Effect of Totum-070 on Lipid Metabolism in Moderate Hypercholesterolemic Subjects

HEART
Start date: February 17, 2021
Phase: N/A
Study type: Interventional

This clinical study aims to assess the efficacy of TOTUM-070, a mix of 5 plant extracts, on lipid metabolism in moderate hypercholesterolemic subjects. The hypothesis is that TOTUM-070, daily consumed, is superior to placebo for decrease of fasting blood LDL-cholesterol concentration (determined by ultracentrifugation method) after 24 weeks of consumption.